Antonio Gualberto
2017
In 2017, Antonio Gualberto earned a total compensation of $1.3M as Head of Development and Chief Medical Officer at Kura Oncology, a 65% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $153,508 |
|---|---|
| Option Awards | $701,130 |
| Salary | $393,100 |
| Other | $10,320 |
| Total | $1,258,058 |
Gualberto received $701.1K in option awards, accounting for 56% of the total pay in 2017.
Gualberto also received $153.5K in non-equity incentive plan, $393.1K in salary and $10.3K in other compensation.
Rankings
In 2017, Antonio Gualberto's compensation ranked 7,877th out of 14,666 executives tracked by ExecPay. In other words, Gualberto earned more than 46.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,877 out of 14,666 | 46th |
Division Manufacturing | 2,955 out of 5,768 | 49th |
Major group Chemicals And Allied Products | 964 out of 2,074 | 54th |
Industry group Drugs | 750 out of 1,730 | 57th |
Industry Pharmaceutical Preparations | 588 out of 1,329 | 56th |
Source: SEC filing on April 26, 2018.
Gualberto's colleagues
We found two more compensation records of executives who worked with Antonio Gualberto at Kura Oncology in 2017.